Sort by

Send to

Choose Destination

Links from PubMed

Items: 14


Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Collins SE, Grant PM, Shafer RW.

Drugs. 2016 Jan;76(1):75-98. doi: 10.1007/s40265-015-0515-6. Review.


Epidemiology and management of antiretroviral-associated cardiovascular disease.

Chastain DB, Henderson H, Stover KR.

Open AIDS J. 2015 Mar 31;9:23-37. doi: 10.2174/1874613601509010023. eCollection 2015.


Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

Benea OE, Streinu-Cercel A, Dorobăţ C, Rugină S, Negruţiu L, Cupşa A, Duiculescu D, Chiriac C, Itu C, Prisăcariu LJ, Iosif I.

Germs. 2014 Sep 1;4(3):59-69. doi: 10.11599/germs.2014.1057. eCollection 2014 Sep.


Serious Non-AIDS events: Immunopathogenesis and interventional strategies.

Hsu DC, Sereti I, Ananworanich J.

AIDS Res Ther. 2013 Dec 13;10(1):29. doi: 10.1186/1742-6405-10-29.


Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.

Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, Charlebois E, Havlir D, Kamya M, Achan J.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):535-41. doi: 10.1097/QAI.0000000000000071.


Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.

Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S, Barlet MH, Nakonz T, Jimenez-Exposito MJ.

Curr HIV Res. 2013 Jun;11(4):333-41.


Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.

Jansen K, Sönnerborg A, Brockmeyer N, Thalme A, Svedhem V, Dupke S, Eychenne JL, Nakonz T, Jimenez-Exposito MJ, Pugliese P.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):564-73. doi: 10.1089/AID.2012.0092. Epub 2012 Nov 27.


Management of dyslipidemia in HIV-infected patients.

Malvestutto CD, Aberg JA.

Clin Lipidol. 2011 Aug;6(4):447-462.


Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE.

Patient Prefer Adherence. 2011;5:357-67. doi: 10.2147/PPA.S22771. Epub 2011 Jul 18.


Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Achenbach CJ, Darin KM, Murphy RL, Katlama C.

Future Virol. 2011 Feb;6(2):157-177.


Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

Melzi S, Carenzi L, Cossu MV, Passerini S, Capetti A, Rizzardini G.

Cholesterol. 2010;2010:271504. doi: 10.1155/2010/271504. Epub 2010 Oct 31.

Free PMC Article

HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Richmond SR, Carper MJ, Lei X, Zhang S, Yarasheski KE, Ramanadham S.

Biochim Biophys Acta. 2010 May;1801(5):559-66. doi: 10.1016/j.bbalip.2010.01.007. Epub 2010 Feb 1.


Atazanavir: its role in HIV treatment.

Wood R.

Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. Review.

Items per page

Supplemental Content

Support Center